Patent ID: 8440411

Claim:
A method of determining pathological angiogenesis, comprising: contacting a sample obtained from a subject with a CD276 probe or primer set and a Ptprn (IA-2) probe or primer set; detecting at least two expression products comprising CD276 and Ptprn (IA-2) in a sample obtained from the subject by performing an assay that detects both CD276 and Ptprn (IA-2); and determining the presence of pathological angiogenesis in the subject by comparing expression level of CD276 RNA/protein and Ptprn (IA-2) RNA/protein in the sample obtained from the subject with the expression level of CD276 RNA/protein and Ptprn (IA-2) RNA/protein in a control sample wherein detection of an increase in expression of the at least two expression products as compared to expression of the at least two expression products in a control sample indicates pathological angiogenesis.